C5a receptor inhibitor avacopan in immunoglobulin A nephropathy—an open-label pilot study
C5a receptor inhibitor avacopan in immunoglobulin A nephropathy—an open-label pilot study
About this item
Full title
Author / Creator
Publisher
England: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
England: Oxford University Press
Subjects
More information
Scope and Contents
Contents
ABSTRACT
Background
Improvement of proteinuria as a marker for disease activity is associated with a better renal outcome in immunoglobulin A nephropathy (IgAN). Complement is an effector pathway in IgA-mediated kidney injury. Avacopan, a selective C5a receptor inhibitor, has previously shown efficacy in anti-neutrophil cytoplasmic antibody–a...
Alternative Titles
Full title
C5a receptor inhibitor avacopan in immunoglobulin A nephropathy—an open-label pilot study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_swepub_ki_se_453687
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_453687
Other Identifiers
ISSN
2048-8505,2048-8513
E-ISSN
2048-8513
DOI
10.1093/ckj/sfab294
